Keep the spray nozzle clean
N-Acetylcysteine (NAC) in schizophrenia resistant to clozapine: A double-blind, randomized, placebo-controlled trial targeting negative symptoms
This was Citius second try for FDA approval, after the regulator rejected Lymphir in July 2023, outlining the need for enhanced product resting requirements. In its resubmitted data package, the company included findings from the from the Phase III Study 302 trial, where treatment with the drug led to an objective response rate of 36.2%, with 8.7% reaching complete response
We haven't really had a new tool in our toolbox from a pharmacotherapy perspective to treat addiction in a long time, said Lembke, noting that some addiction specialists are already prescribing GLP-1s off-label, especially when other treatments have failed
And they work great together
Bn mun to mt website